<DOC>
	<DOCNO>NCT01306318</DOCNO>
	<brief_summary>The primary objective study compare bioavailabilities single fix dose combination eperisone 50 mg plus diclofenac 50 mg capsule bioavailabilities eperisone 50 mg tablet diclofenac 50 mg tablet healthy human adult male subject fasting condition .</brief_summary>
	<brief_title>A Clinical Study Healthy Male Volunteers Compare Bioequivalence Fixed Dose Combination Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg Capsule With Eperisone Hydrochloride 50mg Diclofenac Sodium 50mg Tablets Under Fasting Conditions ( Study 013-10 )</brief_title>
	<detailed_description>The primary objective study compare single-dose oral bioavailabilities eperisone diclofenac Epry-D ( contain eperisone hydrochloride 50 mg diclofenac sodium 50 mg ) capsule Eisai Pharmaceuticals India Private Limited , India Epry ( eperisone hydrochloride ) 50 mg tablet Eisai Pharmaceuticals India Pvt . Ltd. , voltaren ( diclofenac sodium ) 50 mg tablet Novartis Pharmaceuticals Ltd. , India healthy human adult male subject fasting condition . The secondary objective study monitor safety tolerability single dose eperisone hydrochloride 50 mg diclofenac sodium 50 mg formulation administer healthy human adult male subject fasting condition . The participant screen demographic data , medical history , general physical examination , 12-lead electrocardiogram ( ECG ) , chest X-ray ( Posterior Anterior view ) , hematology , clinical bio- chemistry , serology , urine analysis , test alcohol drug abuse . A total 24 healthy adult male volunteer participant house clinical study facility least 11 hour administration Investigational Product ( IP ) continue remain clinical study facility least 12 hour administration IP study period . After overnight fast least 10 hour , either one Epry-D capsule one Epry 50 mg tablet one Voltaren 50 mg tablet administer orally participant sit posture , 240 plus minus 2 mL water room temperature , study period , per randomization schedule . Administration IP perform trained study personnel . Dosing activity follow mouth check ass compliance dosing . A total 22 ( 6 mL ) blood sample collect subject pre-specified vacuum tube contain K2 EDTA study period .</detailed_description>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Eperisone</mesh_term>
	<criteria>Inclusion Criteria Normal healthy human adult male volunteer 1845 year ( age inclusive ) age , give write informed consent willing participate study . Volunteer Body Mass Index 18.50 24.90 Kg/m2 ( inclusive ) . Volunteer evidence underlie disease prestudy screening , medical history , physical examination laboratory investigation perform within 21 day prior commencement study Volunteer whose prestudy screen laboratory test either normal within acceptable limit consider Investigator clinical significance respect participation study . Volunteer negative test alcohol drug abuse , hepatitis B C negative nonreactive antibody human immunodeficiency virus ( HIV ) 1 2 rapid plasma reagin ( RPR ) . Volunteer 12 lead electrocardiogram ( ECG ) record within normal limit . Volunteer normal chest Xray take within 6 month day dose . Volunteer available entire study period capable understanding communicating investigator clinical study facility staff . Exclusion Criteria Volunteer allergic eperisone and/or diclofenac component formulation relate drug . Volunteer history presence significant cardiovascular , respiratory , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological psychiatric disease . More specifically , volunteer history presence follow significant condition : 1 . Alcohol dependence , alcohol abuse drug abuse within past one year , recent current alcohol abuse ( &gt; 5 units/week , 1 unit= 10 mL 8 g pure alcohol ) suspect abuse . 2 . History chronic smoking ( 10 unit per day cigarette , bidis , form ) chronic consumption tobacco product . 3 . Asthma , urticaria allergic type reaction take medication . 4 . Clinically significant illness within 4 week start study . 5 . Hypersensitivity heparin . History clinically relevant allergy ( except untreated , asymptomatic , seasonal allergy time dose ) allergic reaction drug . History Vascular collapse . Volunteer schedule surgery within 7 day study completion . Volunteer , completion clinical bioequivalence study otherwise would donate excess 350 mL blood last 90 day . Volunteer take prescription medication overthecounter product ( include vitamin product natural origin ) within 14 day prior administration IP period 1 , include topical medication mean systemic absorption . Volunteer hospitalize within 28 day prior administration study medication . Volunteer pulse rate le 60/min 100/min . Volunteer history difficulty swallow . Volunteer unsuitable vein repeat venipuncture . Any abnormal laboratory value physical finding may interfere interpretation test result cause health hazard volunteer participates study . Volunteer Systolic blood pressure le 90 mm Hg 150 mm Hg Diastolic blood pressure le 60 mm Hg 90 mm Hg . Minor deviation ( 24 mm Hg ) checkin may acceptable discretion Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>